Drugs / RAY1216
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06362460 | Sep → Nov 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT05829551 | May → Aug 2022 | COVID-19 | Guangdong Raynovent Biotech Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial · 1 met primary | ||||||
| Phase 3 | NCT05620160 | Nov 2022 → Jan 2023 | — | Guangdong Raynovent Biotech Co., Ltd | Completed | Met primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-04-03 | Guangdong Raynovent Biotech Co., Ltd | Results 全球首个拟肽类3CL单药抗新冠病毒一类新药来瑞特韦从基础机制到临床试验学术研究成果陆续发表于国际顶刊和国际权威期刊子刊 raynovent.com ↗
来瑞特韦单药治疗可显著缩短至临床持续恢复时间，尤其是病毒核酸检测阳性72小时内服药和高病毒载量的亚组人群。 |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-04-03 | Guangdong Raynovent Biotech Co., Ltd | 全球首个拟肽类3CL单药抗新冠病毒一类新药来瑞特韦从基础机制到临床试验学术研究成果陆续发表于国际顶刊和国际权威期刊子刊 raynovent.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAY1216 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05829551 ↗ |
| Action | Inhibit | “inhibitor of SARS-CoV-2 main protease.” PMID 38188690 ↗ Dec 2023 |
| Modality | Small molecule | “α-ketoamide based peptidomimetic inhibitor” PMID 38188690 ↗ Dec 2023 |
| Route | Oral | “400mg RAY1216 tablet orally three times daily for 5 days.” NCT05620160 ↗ |